公开(公告)号：US20240285640A1

公开(公告)日：2024-08-29

申请号：US18039282

申请日：2021-11-30

Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.

Inventor： Nanhai HE ,  Peng CHEN ,  Zhiyong YU ,  Yang LU

IPC: A61K31/5377 ,  A61K9/00 ,  A61K31/4152 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K31/5377 ,  A61K9/0019 ,  A61K31/4152 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/545

Abstract: A combination therapy for treating PIK3CA-mutated cancer, comprising administering a PI3K inhibitor, a prostaglandin receptor (PGE2) inhibitor, and a PD-1 inhibitor to a subject in need thereof. The anti-tumor activity brought about by a three-drug combination method is significantly superior to that brought about by a two-drug combination method of the PI3K inhibitor and the PD-1 inhibitor, and the prostaglandin receptor (PGE2) and the PD-1 inhibitor.